Urelumab Biosimilar - Research Grade

Lee et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. Journal of Experimental & Clinical Cancer Research, 2023, 42, 272

Lee, K. Y., et al. Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. Theranostics, 2026, 16(1), 17-36. 23

Human

4-1BB

>1mg/ml

Human IgG1

Anti-Mouse 4-1BB (3H3) In Vivo Antibody - Low Endotoxin (ICH1036), Anti-Mouse 4-1BB (LOB12.3) In Vivo Antibody - Low Endotoxin (ICH1274), Utomilumab Biosimilar - Research Grade (ICH5014), Evunzekibart Biosimilar - Research Grade (ICH5236), Exlinkibart Biosimilar - Research Grade (ICH5541)

https://www.imgt.org/mAb-DB/

ICH3002

Q07011

3604

RRID:AB_2921564

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of urelumab, a fully human agonist antibody directed against 4-1BB (CD137, TNFRSF9). It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary use. The reagent reproduces the antigen-binding specificity of the originator against the human 4-1BB target, making it useful as a defined tool for interrogating 4-1BB costimulatory signaling, as a positive control or benchmarking reagent in binding and functional screens, and in the development and characterization of downstream biologics (for example agonist-antibody engineering, ADCC/ADC workflows, and comparator studies). It supplied unconjugated so users can apply their own detection or conjugation chemistry. Research-grade material is offered at low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities suitable for in-vitro assays, cell-based systems, and preclinical model work. Because it is built around the human 4-1BB target rather than the formulated therapeutic, it should be treated as a characterization and control reagent, not a substitute for the licensed product. 4-1BB (CD137, encoded by TNFRSF9) is a member of the tumor necrosis factor receptor superfamily and functions as an inducible costimulatory receptor. It is largely absent on resting T cells and is upregulated following activation, and it is also expressed on activated NK and NKT cells, regulatory T cells, dendritic cells, monocytes, and other myeloid populations. Engagement by its natural ligand 4-1BBL (CD137L, TNFSF9) drives receptor trimerization and higher-order clustering, recruiting TRAF1/TRAF2 adaptors and activating NF-kB and MAPK signaling. The resulting costimulation promotes T cell proliferation, survival (anti-apoptotic signaling), cytokine secretion such as IL-2 and IFN-gamma, and enhanced cytotoxic effector function, particularly in CD8+ T cells. Because of this activity, 4-1BB is a well-studied target for cancer immunotherapy and is a common costimulatory domain in engineered receptor constructs.

4-1BB ligand receptor, T-cell antigen 4-1BB, Tnfrsf9, Ila, Ly63, CD137

Detects human CD137. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Urelumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Urelumab (anti-4-1BB) Biosimilar

Q: Is the Urelumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Urelumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Urelumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Urelumab that binds human 4-1BB.